COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear. Research ...

IPG is pretty much holding it together as it waits to complete its merger with Omnicom, reporting a 3.5% decline in organic ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who could benefit.

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...